Bristol Myers Squibb Target of Unusually Large Options Trading (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) was the recipient of some unusual options trading on Tuesday. Stock traders purchased 53,552 call options on the stock. This is an increase of 135% compared to the typical daily volume of 22,749 call options.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Cantor Fitzgerald lifted their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Guggenheim reiterated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Finally, HSBC increased their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $57.63 on Wednesday. The firm’s fifty day moving average is $57.00 and its two-hundred day moving average is $57.41. The firm has a market cap of $117.68 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 0.17 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the business posted $1.80 EPS. The company’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb will post 6.32 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently made changes to their positions in BMY. Basecamp Wealth Advisors LLC grew its position in Bristol Myers Squibb by 13.8% during the first quarter. Basecamp Wealth Advisors LLC now owns 6,462 shares of the biopharmaceutical company’s stock valued at $392,000 after buying an additional 786 shares during the period. FAS Wealth Partners Inc. raised its position in shares of Bristol Myers Squibb by 2.1% in the first quarter. FAS Wealth Partners Inc. now owns 12,355 shares of the biopharmaceutical company’s stock worth $749,000 after acquiring an additional 259 shares during the period. Parallel Advisors LLC raised its position in shares of Bristol Myers Squibb by 6.6% in the first quarter. Parallel Advisors LLC now owns 30,078 shares of the biopharmaceutical company’s stock worth $1,824,000 after acquiring an additional 1,868 shares during the period. NewEdge Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 12.9% during the 1st quarter. NewEdge Advisors LLC now owns 226,056 shares of the biopharmaceutical company’s stock worth $13,710,000 after acquiring an additional 25,771 shares in the last quarter. Finally, First Nebraska Trust Co acquired a new stake in shares of Bristol Myers Squibb during the 1st quarter valued at about $662,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Unusual options activity turned constructive, with investors buying 53,552 call options on Bristol Myers Squibb, roughly 135% above the stock’s normal call volume. That suggests traders are positioning for more upside.
• Positive Sentiment: Several recent writeups highlighted Bristol Myers Squibb as a top value and momentum name, reinforcing the view that the stock may remain attractive to investors looking for defensive healthcare exposure and earnings stability. Article on BMY as a top value stock
• Neutral Sentiment: Market commentary also pointed to BMY as a stock that recently outperformed the broader market, which may be supporting near-term trading interest but is not a major new fundamental catalyst. Article on BMY exceeding market returns
• Negative Sentiment: One healthcare article raised concern about potential risk from proposed Medicare drug price negotiation updates, which could pressure long-term pricing and margins for large pharma names like Bristol Myers Squibb. Article on Medicare drug price negotiation risk

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.